The therapeutic approach for HCC remains focused on curative treatments for early stages (resection, ablation, transplantation) or palliative systemic therapies for advanced disease (tyrosine kinase inhibitors [TKIs] and VEGF inhibitors) and immunotherapies (i.e., programmed death 1 [PD-1]/programmed cell death-ligand 1 [PD-L1] inhibitors and anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] antibodies) (Sadagopan et al., 2024
Over up to 10 years of follow-up, GLP-1 therapy was associated with lower rates of cirrhosis complications compared with surgery
Steady state, the point where drug levels plateau because the amount entering the body equals the amount being cleared, takes approximately four to five half-lives to achieve
GLP-1 medications work in several different ways to promote weight loss: 1) by mimicking a naturally occurring GLP-1 hormone in our GI tract, which in turn regulates our insulin and blood sugar levels, 2) by acting in the area of the brain that regulates our hunger cues, and 3) slows stomach emptying which results in feeling fuller for a longer period of time